Cancer News

Isatuximab in Multiple Myeloma (08/27/2019)

The addition of isatuximab to pomalidomide and low-dose dexamethasone significantly improved PFS and overall response rate among patients with relapsed or refractory multiple myeloma, according to randomized phase 3 study results presented at ASCO Annual Meeting. Isatuximab (Sanofi) is a novel anti-CD38 monoclonal antibody with multiple modes of action for killing tumor cells, including direct... Continue Reading

FDA Approves New Treatment for Multiple Myeloma (07/05/2019)

The FDA has granted accelerated approval to selinexor (Xpovio; Karyopharm Therapeutics) tablets in combination with the corticosteroid dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who received ≥4 previous therapies and whose disease is resistant to several other treatment types. “While there is no cure for multiple myeloma, there are FDA-approved... Continue Reading

Darzalex Approved for Newly Diagnosed Stem Cell Transplant Ineligible Multiple Myeloma Patients (07/01/2019)

Darzalex (daratumumab) in combination with Revlimid (lenalidomide) and dexamethasone has been approved by the US Food and Drug Administration for treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. Approval was based on MAIA (NCT02252172), an open-label, randomized (1:1), active-controlled phase 3 study, comparing dartumumab (16 mg/kg) in... Continue Reading

U.S. Food and Drug Administration Approves Empliciti® Plus Pomalidomide to Treat Certain Patients with Relapsed or Refractory Multiple Myeloma (11/12/2018)

The U.S. Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.1 About Empliciti Empliciti is an immunostimulatory antibody that specifically targets Signaling …

Continue reading "U.S. Food and Drug Administration Approves Empliciti® Plus Pomalidomide to Treat Certain Patients with Relapsed or Refractory Multiple Myeloma"

AbbVie and the International Myeloma Foundation Partner to Study Role of a Genetic Mutation in Multiple Myeloma (03/28/2018)

AbbVie a research and development-based global biopharmaceutical company, and the International Myeloma Foundation (IMF) today announced they have entered into a collaboration to conduct a landmark retrospective chart review study to better understand and help manage multiple myeloma (MM), the second most common blood cancer.1 “There are significant knowledge gaps about multiple myeloma, and among …

Continue reading "AbbVie and the International Myeloma Foundation Partner to Study Role of a Genetic Mutation in Multiple Myeloma"

CRISPR Enhances Cancer Immunotherapy (03/14/2018)

Gene editing expands reach of therapeutic T cells, in mice CancerConnect News: Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient’s own immune cells — called T cells — and supercharging them to home in on and attack specific blood cancers, such as …

Continue reading "CRISPR Enhances Cancer Immunotherapy"

Darzalex-Effective Treatment for Smoldering Multiple Myeloma (03/07/2018)

CancerConnect News: The use of Darzalex (daratumumab) in smoldering myeloma may be effective in delaying the time to disease progression. These results were presented at the 2017 annual meeting of the American Society of Hematology (ASH). Multiple myeloma (MM) is the second most common blood cancer in the United States, with over 30,000 diagnoses expected …

Continue reading "Darzalex-Effective Treatment for Smoldering Multiple Myeloma"

Kyprolis Improves Survival in Recurrent Multiple Myeloma (02/08/2018)

CancerConnect News: The addition of Kyprolis® (carfilzomib) to the standard treatment regimen, Revlimid® (lenalidomide) and dexamethasone, improves survival for patients with multiple myeloma whose disease progressed or recurred following prior therapies. These results were recently presented at the 2017 annual meeting of the American Society of Hematology (ASH). About Multiple Myeloma In the United States …

Continue reading "Kyprolis Improves Survival in Recurrent Multiple Myeloma"

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor (02/07/2018)

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary hematologist/oncologist carefully, rely on people you trust including nurses and other health care professionals who make help with recommendations.  Make sure your doctor is someone you …

Continue reading "Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor"

Xgeva Approved for The Treatment of Multiple Myeloma (01/17/2018)

CancerConnect News: The US Food and Drug Administration (FDA) has expanded the approval of Xgeva (denosumab) for the prevention of skeletal-related events in patients with bone metastasis from multiple myeloma. In multiple myeloma, plasma cells infiltrate the bone marrow, spreading into the cavities of all the large bones of the body. In a majority of …

Continue reading "Xgeva Approved for The Treatment of Multiple Myeloma"